Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
Complete Title: Randomized phase II study of belumosudil vs. placebo for preemptive treatment of chronic graft-versus-host disease
Trial Phase: II
Investigator: Stephanie Lee
This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the need for starting additional immune suppressive medications.
Keywords:
- Graft Versus Host Disease, Chronic (cGVHD)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Stephanie Lee
RG1123523
NCT05996627
Randomized phase II study of belumosudil vs. placebo for preemptive treatment of chronic graft-versus-host disease
Graft Versus Host Disease, Chronic (cGVHD)